May 23 (Reuters) - Moderna MRNA.O said on Friday it had filed a marketing application for an updated COVID vaccine to the U.S. Food and Drug Administration.
The company said the submission is based on guidance from the FDA, which advised that COVID-19 vaccines should be updated to target newer strains that are a part of JN.1 lineage, with a preference for the LP.8.1 variant.
(Reporting by Christy Santhosh in Bengaluru; Editing by Mohammed Safi Shamsi)
((Christy.Santhosh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.